Cholangiocarcinoma (CCA) is one of the most aggressive tumors of the hepatobiliary system and is often only diagnosed at an advanced stage. Advances in molecular diagnostics and targeted therapy are increasingly opening up personalized treatment options.
Autoren
- Dr. oec. Odile Schwarz-Herion
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
- approved FGFR inhibitors pemigatinib and futibatinib
- BRAF-V600E
- Cholangiocarcinoma
- Clinical studies Cholangiocarcinoma
- Combination of dabrafenib and trametinib
- Dabrafenib Trametinib
- dMMR
- Entrectinib
- extrahepatic cholangiocarcinoma
- FGFR inhibitors
- FGFR2 fusion
- FIGHT-202 study
- FOENIX-CCA2 study
- Futibatinib
- HER2 amplification
- HER2-positive extrahepatic CCA
- HER2-targeted therapy
- IDH1 mutation
- intrahepatic cholangiocarcinoma
- Ivosidenib effective second-line therapy
- Larotrectinib
- molecular alterations
- molecular diagnostics
- MSI-H
- Next-generation sequencing
- NGS profiling
- NTRK merger
- NTRK mergers
- Pembrolizumab
- Pemigatinib in previously treated patients with FGFR2 fusions
- Personalized oncology
- Prognosis and therapy
- Targeted therapy
- Trastuzumab-based combinations
- TRK Inhibitors
- Tumor Board Switzerland
- tumor-agnostic therapies such as larotrectinib or entrectinib
- Tumors with BRAF V600E mutations
You May Also Like
- From symptom to diagnosis
Pneumology – tracheal and bronchial calcifications
- Tinea capitis: Current Guidelines and Recommendations
What should be kept in mind when treating adult patients?
- Geriatric patients
Micronutrient Intake in Older Adults
- Crohn's disease: focus on long-term results
“Top-down” approach or classic step therapy?
- SwissDiab Study: New Analysis Published
How are diabetes complications associated with quality of life?
- Pre-acclimatization on Mount Everest
Exploring the physiological limits
- Viloxazine for ADHD
A non-stimulating option—but with limited evidence
- Preclinical study on phytotherapeutic agent